BridgeBio Pharma, Inc. (BBIO)

NMS – Real vaqt narxi. Valyuta: USD

65.95

+1.27 (1.96%)

Yopilishda: May 12, 2026, 4:00 PM EDT

13.05.2026

BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches

BridgeBio Pharma NASDAQ: BBIO executives used a BofA healthcare conference appearance in Las Vegas to reiterate confidence in the commercial trajectory of Attruby and outline expectations for three potential near-term product launches from the company's late-stage pipeline.

13.05.2026

BridgeBio Pharma, Inc. (BBIO) Presents at Bank of America Global Healthcare Conference 2026 Transcript

12.05.2026

BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1

- Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstrating the rapid and durable benefit of encaleret across key clinical parameters in ADH1

11.05.2026

Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure

-Acoramidis increased sTTR early and significantly reduced intra-individual sTTR variability versus placebo (p

08.05.2026

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on May 6, 2026, the compensation committee of BridgeBio's board of directors approved equity grants to 52 new employees in restricted stock units for an aggregate of 115,007 shares of the Company's common stock. One-fourth of the shares underlying each employee's restricted stock units will vest on May 16, 2027, with one-twelfth of the remaining shares underlying each such employee's restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee's continued employment with the Company or one of its subsidiaries on such vesting dates.

08.05.2026

BridgeBio Pharma, Inc. (BBIO) Q1 2026 Earnings Call Transcript

07.05.2026

BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates

BridgeBio Pharma (BBIO) came out with a quarterly loss of $0.84 per share versus the Zacks Consensus Estimate of a loss of $0.7. This compares to a loss of $0.88 per share a year ago.

Videolar

No Data

There is no data to display

Press-relizlar

12.05.2026

BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1

- Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstrating the rapid and durable benefit of encaleret across key clinical parameters in ADH1

11.05.2026

Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure

-Acoramidis increased sTTR early and significantly reduced intra-individual sTTR variability versus placebo (p

08.05.2026

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

07.05.2026

BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates

PALO ALTO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today its financial results for the first quarter ended March 31, 2026, and provided an update on Attruby's commercial progress.

BridgeBio Pharma, Inc. (BBIO)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

BridgeBio Pharma, Inc. (BBIO)

BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches

BridgeBio Pharma, Inc. (BBIO) Presents at Bank of America Global Healthcare Conference 2026 Transcript

BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1

Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma, Inc. (BBIO) Q1 2026 Earnings Call Transcript

BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates

Videolar

No Data

Press-relizlar

BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1

Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates

BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches

BridgeBio Pharma, Inc. (BBIO) Presents at Bank of America Global Healthcare Conference 2026 Transcript

BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1

Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma, Inc. (BBIO) Q1 2026 Earnings Call Transcript

BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates

Videolar

No Data

Press-relizlar

BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1

Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates

Search stocks

BridgeBio Pharma, Inc. (BBIO)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

BridgeBio Pharma, Inc. (BBIO)

BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches

BridgeBio Pharma, Inc. (BBIO) Presents at Bank of America Global Healthcare Conference 2026 Transcript

BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1

Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma, Inc. (BBIO) Q1 2026 Earnings Call Transcript

BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates

Videolar

No Data

Press-relizlar

BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1

Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates

BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches

BridgeBio Pharma, Inc. (BBIO) Presents at Bank of America Global Healthcare Conference 2026 Transcript

BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1

Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma, Inc. (BBIO) Q1 2026 Earnings Call Transcript

BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates

Videolar

No Data

Press-relizlar

BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1

Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates